Amgen has its first direct competition in the KRAS inhibitor class following FDA approval of Mirati's adagrasib as Krazati for a form of lung cancer. Krazati has been cleared as a treatment for ...
Mirati Therapeutics is the subject of takeover speculation in the biopharma sector once again, as it waits for the FDA's decision on its KRAS inhibitor adagrasib in non-small cell lung cancer (NSCLC).
Georgia Southern Marketing Professor Dr. Christian Barney joined Morning Break with some tips to help you navigate your online shopping spree.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback